Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 463 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Three Brothers Under The Age Of 6 Are All Fighting The... February 7, 2020 Programme Highlights of the ESMO Virtual Congress 2020 [ESMO Media Alert] August 28, 2020 Pregnant Mom Had to Fight for a Diagnosis After Finding a... August 2, 2021 Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... November 5, 2025 Load more HOT NEWS 105-Year-Old Woman Sets Record For 100-Meter Dash Teacher Visits Student Battling Cancer At Home To Help With His... Making real change: 4 ways we’ve influenced cancer policy Saying YES: Inspiring a Diverse Generation of Cancer Scientists
